Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorphenesin Carbamate SCHEMBL2939463 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNASMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL5354587 | 0.85 | CYP1A2 (0.74) | CYP1A2LMNAKDM4EMAPK1POLB | |
| SCHEMBL18309828 | 0.84 | CYP1A2 (0.72) | CYP1A2LMNASMN1; SMN2KDM4EPOLB | |
| SCHEMBL21977218 | 0.83 | CYP1A2 (0.71) | CYP1A2LMNASMN1; SMN2KDM4EPOLB | |
| Carbamic Acid SCHEMBL34493 | 0.81 | CYP1A2 (0.68) | CYP1A2LMNAMAPK1POLBMAPT | |
| SCHEMBL9654944 | 0.80 | CYP1A2 (0.67) | CYP1A2LMNASMN1; SMN2MAPK1POLB | |
| SCHEMBL11140249 | 0.80 | CYP1A2 (0.66) | CYP1A2LMNAMAPK1POLBMAPT | |
| SCHEMBL11649744 | 0.79 | CYP1A2 (0.65) | CYP1A2LMNASMN1; SMN2MAPK1POLB | |
| SCHEMBL11546333 | 0.79 | CYP1A2 (0.65) | CYP1A2LMNAMAPK1POLBMAPT | |
| SCHEMBL5360069 | 0.78 | CYP1A2 (0.64) | CYP1A2LMNASMN1; SMN2MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539297-B2 | Composition for inhibiting cancer metastasis and treating cancer | ONCOCROSS CO., LTD. (KR) | 2026-02-03 | — | — | US | claimed |
| US-12502371-B2 | Drug for treating and preventing dementia | NUMAN LABO LLC (JP) | 2025-12-23 | — | — | US | claimed |
| US-20250191770-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2025-06-12 | — | — | US | claimed |
| EP-4565196-A1 | A PRESERVATIVE COMPOSITION | AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG (DE) | 2025-06-11 | — | — | EP | claimed |
| EP-3572080-B1 | COMPOSITION FOR INHIBITING CANCER METASTASIS AND TREATING CANCER | ONCOCROSS CO LTD (KR) | 2024-11-13 | — | — | EP | claimed |
| EP-4380599-A1 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ACNE | FB Dermo S.r.l. (IT) | 2024-06-12 | — | — | EP | claimed |
| WO-2024028266-A1 | A PRESERVATIVE COMPOSITION | BRAIN Biotech AG (DE) | 2024-02-08 | — | — | WO | claimed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| US-20230329630-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2023-10-19 | — | — | US | claimed |
| EP-4259287-A1 | A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES | Symrise AG (DE) | 2023-10-18 | — | — | EP | claimed |
| US-20070065463-A1 | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions | AFGIN PHARMA LLC | 2007-03-22 | — | — | US | claimed |
| WO-2006130982-A1 | COMPOSITIONS AND METHODS FOR ENHANCING NITRIC OXIDE DELIVERY | UNIVERSITY OF MANITOBA (CA) | 2006-12-14 | — | — | WO | claimed |
| US-20050008702-A1 | Rupturing controlled release device having a preformed passageway | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2005-01-13 | — | — | US | claimed |
| EP-1362585-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING A COX-II INHIBITOR AND A MUSCLE RELAXANT | Osmotica Corp. (VG) | 2003-11-19 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| US-4722938-A | COMBINED WITH NON-STEROIDAL ANTIINFLAMMATORY DRUG | ANALGESIC ASSOCIATES (US) | 1988-02-02 | — | — | US | claimed |
| EP-0205492-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE, Abraham (US) | 1986-12-30 | — | — | EP | claimed |
| WO-1986003681-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE ABRAHAM | 1986-07-03 | — | — | WO | claimed |
| US-3968147-A | COORDINATION CATALYST | MONSANTO COMPANY (US) | 1976-07-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502371-B2 | Drug for treating and preventing dementia | ACHE, BCHE, CHRM3 | CYP1A2 1292/4885LMNA 3583/4885SMN1; SMN2 2167/4885 |
| US-12539297-B2 | Composition for inhibiting cancer metastasis and treating cancer | CTSB, CTSE, CALCB | CYP1A2 3973/4885LMNA 3914/4885SMN1; SMN2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.